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ABSTRACT
In multiple myeloma, elevated MYC expression is related to disease initiation 
and progression. We found that in myeloma cell lines, MYC gene amplifications were 
common and correlated with MYC mRNA and protein. In primary cell samples MYC 
mRNA levels were also relatively high; however gene copy number alterations were 
uncommon. Elevated levels of MYC in primary myeloma cells have been reported 
to arise from complex genetic aberrations and are more common than previously 
thought. Thus, elevated MYC expression is achieved differently in myeloma cell lines 
and primary cells. Sensitivity of myeloma cell lines to the MYC inhibitor 10058-F4 
correlated with MYC expression, supporting that the activity of 10058-F4 was through 
specific inhibition of MYC.
INTRODUCTION
Multiple myeloma is the second most common 
hematological malignancy and accounts for about 2% of 
cancer-related deaths. The cancer cells arise from post-
germinal center plasma cells and usually reside in the 
bone marrow. Myeloma is preceded by a benign condition 
termed monoclonal gammopathy of undetermined 
significance (MGUS), [1] and the annual risk of 
progression to myeloma is about 1%. [2] Treatment of 
multiple myeloma has improved during the last decades 
by the introduction of proteasome inhibitors such as 
bortezomib and carfilzomib as well as immunomodulatory 
drugs (IMIDs) such as thalidomide and lenalidomide. 
However; the median overall survival time from diagnosis 
is still no more than 5–7 years. [3, 4]
The transcription factor c-MYC (hereafter termed 
MYC) and the related N-MYC and L-MYC oncogenes 
are involved in the development of up to 70% of all 
cancers. [5] Under normal conditions MYC increases 
cell proliferation and halts differentiation. [6] Abnormal 
MYC activity has been shown to be associated with many 
features of cancer cells including cell metabolism and 
proliferation. [7] In multiple myeloma it was commonly 
thought that activation of MYC was a late-stage event. [8] 
The importance of MYC in myeloma disease progression 
has lately become clearer, and increased MYC activity 
has been implicated in progression from MGUS to full-
blown myeloma. [9–12] Recently, two papers showed 
that complex rearrangements positioning MYC in the 
proximity of super-enhancers caused elevated MYC 
expression in primary myeloma cells. [13, 14] Moreover, 
MYC was shown to be the most frequent translocation 
partner in aberrations involving the immunoglobulin light 
chains. [15] Altogether, MYC rearrangements were found 
in nearly half of the myeloma patients leaving MYC the 
most commonly mutated gene in multiple myeloma. [13]
We have earlier shown that MYC expression 
was important for in vitro survival of myeloma cells 
using different approaches for targeting MYC. [16–18] 
The question we wanted to address in this study was 
whether the vulnerability of multiple myeloma cells 
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for MYC inhibition correlated to cellular levels of 
MYC. Pharmacological targeting of MYC activity has 
been challenging. One option is to use small molecule 
inhibitors that target MYC-MAX heterodimerization 
thereby preventing transactivation of MYC target genes. 
[19, 20] We found that the small molecule inhibitor of 
MYC, 10058-F4, suppressed proliferation and survival 
of myeloma cells, arguing for a distinct role of MYC in 
multiple myeloma. The importance of MYC was further 
supported by an inverse correlation between IC50 of the 
inhibitor and the level of MYC in myeloma cell lines.
RESULTS
We have earlier shown that the small molecule 
MYC inhibitor 10058-F4 induces apoptosis in myeloma 
cell lines and primary cells. [17, 20] The inhibitor 
downregulated MYC protein and mRNA in a dose-
dependent manner in myeloma cells (Supplemenatry 
Figure 1A–1C). We wanted to find out if the baseline 
MYC expression could determine myeloma cell 
sensitivity to 10058-F4. A panel (n = 11) of myeloma cell 
lines were treated with increasing amounts of inhibitor 
for three days. The combined effects on cell proliferation 
and viability were determined using CellTiter Glo which 
measures the ATP content in cells (Supplementary 
Figure 2). IC50 values were determined from dose-
response curves and related to MYC transcript numbers 
measured by the nCounter Nanostring technology 
(Figure 1A, Supplementary Figure 3A) and protein 
levels using immunoblotting (Figure 1B, Supplementary 
Figure 3B, 3C). There was a negative correlation 
between IC50 values and mRNA (R2 = 0, 548) or protein 
(R2 = 0, 585) levels. Taken together, the correlation 
between MYC expression and sensitivity to the 10058-
F4 compound, supports that 10058-F4 is a relatively 
specific inhibitor of MYC activity. Secondly, the finding 
that the cell lines with the highest MYC concentration 
were the most sensitive suggests that cell lines expressing 
high levels of MYC are more dependent on the MYC 
expression for proliferation or survival than cell lines 
expressing lower amounts of MYC.
Next, we measured MYC gene copy numbers 
in all 11 myeloma cell lines using PCR with primers 
for exon 3 (Supplementary Figure 3D) and correlated 
the copy numbers with MYC mRNA, as well as with 
protein levels (Supplementary Figure 3A, 3B and 3C). 
In cell lines, the MYC gene copy numbers varied from 
two to nine. The measured copy numbers were almost 
identical using primers that were specific for exon 1 
and exon 2 (Supplementary Figure 3D), indicating the 
presence of the whole gene rather than fragments of 
the gene. Interestingly, the MYC gene copy numbers 
correlated well with both mRNA (R2 = 0.847) and protein 
(R2 = 0.607) levels (Figure 2A and 2B). The results thus 
indicate that the main determinant of elevated MYC 
expression in myeloma cell lines is amplification of the 
MYC gene.
We went on to investigate the variation in MYC 
gene copy numbers in myeloma patient samples by the 
same method as applied for cell lines. Interestingly, most 
of the primary samples (n = 21) had two copies of the 
MYC gene and the samples deviating from this (n = 7) 
had MYC gene copies varying from 1 to 4 (data not 
shown). The levels of MYC mRNA, on the other hand, 
showed remarkable variation (Figure 3A). Thus, in 
contrast to myeloma cell lines, MYC levels in primary 
cells apparently are not determined by the number of gene 
copies as measured here, but by other mechanisms.
Interestingly, we originally compared MYC mRNA 
levels in cell lines and primary cells applying GAPDH 
mRNA as the only reference, getting higher MYC levels in 
primary cells than in myeloma cell lines. However, when 
comparing GAPDH mRNA levels in cell lines with primary 
cells using the Nanostring nCounter technology and using 
several genes as reference; it turned out that the difference 
in GAPDH mRNA was even greater than the difference in 
MYC mRNA. Thus, when comparing MYC mRNA levels 
in primary cells and cell lines, the patient cells as a group 
had lower MYC expression levels than cell lines (Figure 3B). 
Patients (n = 28) had a median MYC level of 2345, range 
660–15969, whereas the cell lines (N = 11) had a median 
level of 8411, range 85–18859. Furthermore, the cell lines 
had a median GAPDH level of 33347, range 23653–59757, 
whereas the primary cells had a median GAPDH level of 
8345, range 2297–15769 (Figure 3C). We also treated the 
primary myeloma samples with the MYC inhibitor to obtain 
IC50 values. However, the cell viability varied and only 18 
out of 28 samples had a viability > 50% without treatment. 
Those samples were included in analysis (data not shown). 
When comparing IC50 values for 10058-F4 in the samples 
with baseline viability > 50% with MYC mRNA expression, 
we were not able to see the same correlation as in cell lines. 
However, analysis of only 18 samples may not be sufficient 
to see such correlations. There was no correlation between 
cell viability in the patient samples and 10058-F4 IC50 
values (n = 28, data not shown).
The primary cells studied were both from newly 
diagnosed, untreated patients (n = 13), as well as from 
treated patients (n = 15), i.e. patients at a later stage of 
disease. Clinical characteristics of the patient samples 
are found in Supplementary Table I. Interestingly, 
the MYC mRNA levels were not different between 
previously treated and untreated patients (Figure 3D), 
indicating that untreated patients had myeloma cells with 
as high MYC expression as patients in later stages of 
disease. These observations suggest that both untreated 
and treated patients may have plasma cells with high 
MYC expression that possibly could be targeted by 
MYC inhibition.
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Figure 1: MYC gene copy numbers determine expression of MYC mRNA and protein in myeloma cell lines. In a panel 
of myeloma cell lines the levels of MYC gene copy numbers as measured by PCR was related to A. MYC mRNA measured using nCounter, 
and B. MYC protein levels measured using immunoblotting and normalized to GAPDH. The slope and R2-values are shown in the plots.
Oncotarget4www.impactjournals.com/oncotarget
Figure 2: Expression of MYC in myeloma cell lines correlated positively with sensitivity to MYC inhibition. The IC50-
values of the MYC inhibitor 10058-F4 calculated from the results shown in Supplementary Figure 2 was compared with A. MYC mRNA 
values or B. MYC/GAPDH relative protein levels. The slope and R2-values are shown in the plots.
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DISCUSSION
The most important data presented here is that 
there was a positive correlation between MYC expression 
and sensitivity to the MYC activity inhibitor, 10058-F4, 
in myeloma cell lines. That finding supports that MYC 
is important for myeloma cell survival and that the 
inhibitor specifically targets MYC. Secondly, although 
both myeloma cell lines and primary cells expressed high 
amounts of MYC, there are differences in the underlying 
mechanisms behind the expression. And thirdly, MYC 
expression was in the same range in plasma cells from 
untreated compared to treated patients indicating that 
MYC activation is an early oncogenic event in multiple 
myeloma.
Cell lines expressing the highest levels of MYC 
were the most sensitive to MYC-inhibition, indicating that 
these cells were more dependent on MYC for survival and 
proliferation than low-expressors. Thus, we hypothesize 
that patients with myeloma cells expressing high levels 
of MYC could benefit from MYC inhibition. MYC 
protein and mRNA are very unstable and may be rapidly 
degraded. When isolating primary myeloma cells from 
bone marrow samples the procedure usually takes a few 
hours and there is a risk that MYC protein and mRNA 
levels are not maintained at the same levels as when the 
cells are situated in the bone marrow. Thus, the most 
reliable way to measure MYC levels in patients could be 
by quantitative in situ immunohistochemistry using bone 
marrow biopsies. Unfortunately, it was not possible for us 
to perform such experiments in this study.
A major concern when applying small molecule 
inhibitors is the specificity of the inhibitor. The 10058-F4 
drug has been proposed to be a specific inhibitor of MYC-
MAX heterodimerization at concentrations < 100 μM. 
[20, 21] However, even if 10058-F4 clearly inhibits the 
MYC-MAX interaction, the compound may also affect 
other molecules within a cell. The correlation between 
MYC expression and sensitivity for the 10058-F4 drug 
found in cell lines indicated that the activity of the drug 
was specifically directed towards MYC activity. As MYC 
is a factor that is functionally non-redundant it may be 
particularly attractive as a therapeutic target. [22] MYC 
could already indirectly be targeted in the clinic since 
many drugs, such as dexamethasone and lenalidomide, 
have been shown to kill myeloma cells concomitantly with 
partial suppression of MYC, [23, 24] albeit, these drugs 
clearly also have other effects.
We found higher MYC mRNA levels in myeloma 
cell lines than in primary cells; although the range was 
approximately the same in these two groups. Nevertheless, 
gene copy number variations in MYC were only common 
in cell lines, indicating that primary cells had other 
ways of increasing MYC levels than cell lines. Indeed, 
recent publications indicate that different rearrangements 
involving MYC cause elevated MYC expression in nearly 
half of newly diagnosed patients. [13–15] MYC expression 
has been reported to affect cell proliferation and energy 
metabolism in rapidly proliferating cancer cells. [7] 
Amplification of the MYC gene seen in myeloma cell 
lines may be a consequence of the selection pressure for 
proliferation and survival in tissue culture flasks. Cell lines 
Figure 3: MYC and GAPDH mRNA levels in primary myeloma cells. A. The levels of MYC mRNA in myeloma patient 
samples (n = 28), P01-P28, were measured using nCounter and the calculated mRNA copy numbers were plotted. Box plots comparing the 
levels of MYC B. and GAPDH C. mRNA in 28 isolated plasma cells from myeloma patients with 11 myeloma cell lines. D. The levels of 
MYC mRNA measured as in A were plotted for treated (n = 15) versus untreated (n = 13) patients in a box plot. The upper and lower borders 
of the box indicate upper and lower quartile, whereas the line inside the box indicates the median value. Whiskers indicate upper and lower 
adjacent values, whereas outside values are indicated by (o) and far out values are indicated by asterisks (*).
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are highly proliferating, whereas primary myeloma cells in 
the bone marrow in general proliferate very slowly, with a 
Ki-67 labelling index less than 5% for most patients. [25] 
Amplification of the MYC gene may be a simple way of 
achieving high MYC levels in cell lines that over years 
have been selected for cell proliferation in vitro. Another 
difference is that, unlike myeloma cell lines, primary 
cells depend on the bone marrow microenvironment and 
are unable to survive in tissue culture. There was also a 
difference in GAPDH expression levels between cell 
lines and primary cells that could reflect differences in 
utilization of glycolysis for ATP production.
In patients, a negative relationship between MYC 
expression and progression-free and overall survival has 
been described, suggesting an important role for MYC in 
the regulation of tumor mass. [14, 26–28] We compared 
the MYC mRNA expression with clinical information 
on progression-free and overall survival in our patient 
samples, but could not find any relationship (data not 
shown). However, the number of informative patients 
was too low to draw any conclusions. Nevertheless, our 
findings that MYC mRNA is as high in untreated patients 
as in patients at later stages of disease suggest that MYC 
may be important during the whole course of disease.
To summarize, our results suggest that many 
myeloma patients, but first of all patients with cells 
expressing high MYC levels, might benefit from MYC 
inhibition. If a specific and clinically applicable MYC-
inhibitor became available, it would be important to 
characterize which patients might benefit from inhibition 
of MYC.
MATERIALS AND METHODS
Cell lines and reagents
A panel of 11 myeloma cell lines was used. Four 
of the cell lines were in-house: OH-2, IH-1, URVIN and 
KJON, whereas 7 were from other sources: INA-6, CAG, 
JJN3 and ANBL-6 were kind gifts from Dr M. Gramatzki 
(University of Erlangen-Nurnberg, Erlangen, Germany), 
Dr J. Epstein (University of Arkansas for Medical 
Sciences, Little Rock, AR, USA), Dr J. Ball (University 
of Birmingham, UK), and Dr D. Jelinek (Mayo Clinic, 
Rochester, MN, USA), respectively, KMS-12-BM was 
obtained from DSMZ (Braunschweig Germany), and 
RPMI-8226 and U266 were from ATCC (Rockville, MD, 
USA). URVIN, INA-6 and ANBL-6 cells were grown in 
10% heat inactivated fetal calf serum (FCS) in RPMI-1640 
(RPMI) supplemented with interleukin (IL)-6 (1 ng/mL) 
(Biosource, Camarillo, CA, USA). CAG, JJN3, KMS-
12-BM, RPMI-8226 and U266 were grown in RPMI 
with 10, 10, 20, 20 or 15% FCS, respectively. OH-2 and 
IH-1 were maintained in 10% heat-inactivated human 
serum (HS) (Department of Immunology and Transfusion 
Medicine, St. Olav’s University Hospital, Trondheim, 
Norway) whereas KJON was maintained in 5% HS, 
all in RPMI and IL-6 (2 ng/mL). Cells were cultured at 
37oC in a humidified atmosphere containing 5% CO2. For 
experiments 2% HS in RPMI was used as medium, with 
IL-6 (1 ng/mL) added for all IL-6 dependent cell lines.
Primary cells
Primary CD138+ myeloma cells were isolated 
from bone marrow specimens included in the Norwegian 
Myeloma Biobank using RoboSep automated cell 
separator and Human CD138 Positive Selection Kit 
(StemCell Technologies, Grenoble, France). The study 
was approved by the Regional Ethics Committee (approval 
# 2011/2029) and all patients had given informed consent. 
Peripheral blood mononuclear cells (PBMC) were 
obtained from EDTA-blood from healthy controls by 
density gradient centrifugation using Lymphoprep (Axis-
Shield, Oslo, Norway).
Nucleic acid extraction
Genomic DNA and total RNA were extracted from 
frozen cell pellets using AllPrep DNA/RNA Micro Kit and 
Qiacube (Qiagen, Venlo, the Netherlands) following the 
manufacturer’s instructions. The concentration and quality 
of DNA and RNA was determined using NanoDrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA), and samples were stored at −80°C until 
further use.
Real-time quantitative reverse transcription 
PCR (qRT-PCR)
Complementary DNA (cDNA) was synthesized 
from total RNA using the High Capacity RNA-to-cDNA 
kit (Applied Biosystems, Carlsbad, CA, USA). PCR was 
performed using StepOne Real-Time PCR System and 
Taqman Gene Expression Assays (Applied Biosystems). 
The comparative Ct method was used to estimate relative 
changes in gene expression using MYC Taqman assay 
(Hs00153408_m1) and GAPDH (Hs99999905_m1) as 
housekeeping gene.
Copy number variation (CNV)
Real-time reverse transcriptase quantitative 
polymerase chain reaction (real-time qPCR) was 
performed using the TaqMan Copy Number Assay 
Hs01764918_cn (MYC, exon 3), Hs00834648_cn 
(MYC, exon 2), Hs02758348_cn (MYC, exon 1), and 
TaqMan Copy Number Reference Assay (RNAse P) for 
internal control (Applied Biosystems). All PCR reactions 
were performed in triplets with genomic DNA using a 
StepOnePlus PCR system (Applied Biosystems). CNV was 
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analyzed using CopyCaller Software (Applied Biosystems) 
and DNA isolated from PBMC was used for calibration.
Gene expression analysis
For mRNA transcript counting the nCounter 
Human Cancer Reference Kit (cat.no GXA-CR1–12) 
and nCounter Technology (Nanostring Technologies, 
Seattle, WA, USA) was used. The standard mRNA Gene-
expression experiment protocol provided by Nanostring 
was used, the only exception being that kit probes were 
diluted 1:2. Briefly, 100 ng total RNA from myeloma 
cell lines or patient samples was hybridized with reporter 
probes overnight at 65°C. The nSolver Analysis Software 
(Nanostring) was used for calculations of transcript 
numbers. Sample data was normalized against internal kit 
positive controls and the following housekeeping genes: 
CLTC, GAPDH, GUSB, HPRT1, PGK1, and TUBB.
Immunoblotting
Cells were treated as indicated, washed with ice-
cold phosphate-buffered saline (PBS) and lysed for 
30′ on ice. The lysis buffer contained 1% NP40 (Sigma-
Aldrich, St Louis, MO, USA), 150 mM NaCl, 50 mM 
Tris-HCl (pH 7.5), a protease inhibitor cocktail (Roche, 
Basel, Switzerland), 1 mM Na
3
VO
4
 and 50 mM NaF. 
Samples were electrophoresed on pre-cast agarose gels 
and blotted onto nitrocellulose membranes using the 
NuPAGE system (Life Technologies, Carlsbad, CA, 
USA). The membranes were blocked with 5% nonfat 
dry milk in Tris-buffered saline with 0.01% Tween 
20 (TBS-T). The primary antibodies used were c-MYC 
(RRID: AB_2148606, Cat# 551102, BD Biosciences, 
Trondheim, Norway), and GAPDH (RRID:AB_2107448, 
Cat# Ab8245, Abcam, Cambridge, UK). The secondary 
antibody was horseradish peroxidase-conjugated goat-
anti-mouse (Dako Cytomation, Glostrup, Denmark). 
Positive bands were detected using the luminescence 
substrate SuperSignal West Femto (Thermo Fisher 
Scientific) and Odyssey Fc imager (LI-COR Biosciences, 
Ltd., Cambridge, UK).
Cell proliferation assay
Cell proliferation was estimated using the CellTiter-
Glo assay (Promega, Madison, WI, USA), that measures 
the cells’ ATP content. The cells were seeded in 100 μL 
per well in white opaque 96 well plates and treated with 
increasing doses of inhibitor for 72 hours. The cell lines 
have different growth rates and, thus, the cell numbers that 
were seeded for each cell line varied from 10000 – 50000 
per well. Assay reagent was added and the plates were 
mixed for 2 min on a shaker. After a 10 min incubation 
in room temperature luminescence was detected using 
a Victor 1420 multilabel counter (PerkinElmer Inc., 
Waltham, MA, USA).
Statistical analysis
Statistical analysis and box plots were made in IBM 
SPSS Statistics 20 (IBM Corp., Armonk, NY, USA).
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